

Synthesis, structural and antimicrobial studies of some 1-[2-(1*H*-benzimidazol-1-yl)acetyl]-2,6-diarylpiperidin-4-ones

**Gopalakrishnan Aridoss, Shanmugasundaram Amirthaganesan, Min Sung Kim,
Byung Gwon Cho, Kwon Taek Lim, and Yeon Tae Jeong***

*Division of Image Science and Information Engineering, Pukyong National University, Busan,
Korea- 608-739*
E-mail: ytjeong@pknu.ac.kr

Entry	Caption	Page No.
Table S1	Mass spectral data [<i>m/z</i> (relative intensity %)] of compounds 21-30	S2
Table S2	Crystal data and structure refinement of 1-Chloroacetyl-3,5-dimethyl-2,6-bis(<i>p</i> -methyl phenyl)piperidin-4-one 20	S3
Figure S1	¹ H NMR spectrum of compound 29	S4
Figure S2	¹³ C NMR spectrum of compound 29	S5
Figure S3	Mass fragmentation pattern for 21	S6
Figure S4	Mass fragmentation pattern for 21	S7
Figure S5	Mass fragmentation pattern for 21	S8
Figure S6	Mass fragmentation pattern for 21	S9
Figure S7	Mass fragmentation pattern for 21	S10
Figure S8	Mass fragmentation pattern for 21	S11
Figure S9	Mass fragmentation pattern for 21	S12
Figure S10	Mass fragmentation pattern for 21	S13

Table S1. Mass spectral data [*m/z* (relative intensity %)] of compounds **21-30**

Entry	A	B	C	D/S	E	F	G	J	K	L	O	P	R	U	V
21	423 (5.3)	159 (2.9)	264 (3.8)	104 (24.8)	249 (3.1)	-	176 (5.2)	119 (22.7)	132 (100)	131 (51.5)	160 (2.61)	132 (100)	119 (22.7)	104 (24.8)	77 (32.0)
22	437 (22.6)	159 (6.5)	278 (14.4)	104 (20.8)	249 (8.5)	-	176 (15.7)	119 (30.3)	132 (100)	-	-	-	119 (30.3)	104 (20.8)	77 (23.4)
23	437 (8.6)	159 (1.7)	278 (1.9)	104 (15.0)	263 (6.4)	262 (6.8)	176 (11.9)	119 (30.5)	132 (100)	131 (48.5)	160 (4.8)	132 (100)	119 (30.5)	104 (15.0)	77 (24.1)
24	459 (14.9)	159 (2.7)	-	122 (21.6)	-	-	176 (13.5)	119 (46.6)	132 (68.2)	131 (99.2)	178 (4.9)	150 (100)	137 (4.2)	104 (18.6)	77 (27.2)
25	473 (11.3)	159 (7.1)	-	122 (14.1)	-	298 (31.5)	176 (18.0)	119 (33.9)	132 (35.3)	131 (100)	178 (6.9)	150 (61.3)	137 (5.4)	104 (16.6)	77 (27.4)
26	491 (2.59)	159 (3.2)	333 (0.8)	138 (12.1)	-	-	176 (9.3)	119 (39.7)	132 (52.2)	131 (100)	194 (2.4)	166 (40.5)	153 (2.6)	104 (17.7)	77 (4.9)
27	505 (5.8)	159 (4.4)	-	138 (5.3)	-	331 (2.3)	176 (33.4)	119 (75.4)	132 (51.9)	131 (100)	194 (5.1)	166 (76.9)	153 (7.3)	104 (17.8)	77 (27.2)
28	579 (1.5)	159 (4.2)	-	-	-	406 (4.5)	176 (11.0)	119 (36.8)	132 (46.7)	131 (100)	-	211 (16.1)	-	104 (17.1)	77 (29.0)
29	593 (0.7)	159 (6.4)	-	-	-	-	176 (20.5)	119 (57.8)	132 (45.3)	131 (100)	-	211 (4.4)	-	104 (21.7)	77 (39.0)
30	465 (59.7)	159 (13.3)	306 (21.5)	118 (14.0)	-	290 (59.5)	176 (26.8)	119 (65.4)	132 (74.9)	131 (80.2)	174 (13.1)	146 (100)	133 (31.8)	104 (14.1)	77 (20.9)

A – Molecular ion-radical; B to V – Fragmented ions

Table S2. Crystal data and structure refinement of 1-Chloroacetyl-3,5-dimethyl-2,6-bis(*p*-methylphenyl)piperidin-4-one **20**

Empirical formula	C ₂₃ H ₂₆ ClNO ₂
Formula weight	383.90
Temperature	293(2) K
Wavelength	0.71073 Å
Crystal system, space group	Triclinic, P-1
Unit cell dimensions	a = 11.9590(4) Å alpha = 95.483(2) deg. b = 14.3697(5) Å beta = 113.333(2) deg. c = 14.7369(5) Å gamma = 110.028(2) deg.
Volume	2104.84(12) Å ³
Z, Calculated density	4, 1.211 Mg/m ³
Absorption coefficient	0.198 mm ⁻¹
F(000)	816
Crystal size	0.26 x 0.20 x 0.20 mm
Theta range for data collection	1.56 to 24.54 deg.
Limiting indices	-13 ≤ h ≤ 13, -16 ≤ k ≤ 16, -17 ≤ l ≤ 17
Reflections collected / unique	36212 / 6958 [R(int.) = 0.0331]
Completeness to theta = 25.00	98.9 %
Absorption correction	Semi-empirical from equivalents
Max. and min. transmission	0.9614 and 0.9503
Refinement method	Full-matrix least-squares on F ²
Data / restraints / parameters	6958 / 0 / 528
Goodness-of-fit on F ²	1.028
Final R indices [I>2sigma(I)]	R1 = 0.0507, wR2 = 0.1411
R indices (all data)	R1 = 0.0740, wR2 = 0.1649
Extinction coefficient	0.0066(15)
Largest diff. peak and hole	0.746 and -0.473 e.Å ⁻³




Figure S1. ¹H NMR spectrum of compound 29




Figure S2. ^{13}C NMR spectrum of compound 29




Figure S3. Mass fragmentation pattern for **21**




Figure S4. Mass fragmentation pattern for 22




Figure S5. Mass fragmentation pattern for 23




Figure S6. Mass fragmentation pattern for 24




Figure S7. Mass fragmentation pattern for 25




Figure S8. Mass fragmentation pattern for **26**




Figure S9: Mass fragmentation pattern for **28**




Figure S10. Mass fragmentation pattern for 30